NOVOMIX 70 Suspension for injection Ref.[50951] Active ingredients: Insulin aspart

Source: European Medicines Agency (EU)  Revision Year: 2020  Publisher: Novo Nordisk A/S, Novo Allé, DK-2880 Bagsværd, Denmark

Product name and form

NovoMix 70 Penfill 100 units/ml suspension for injection in cartridge.

NovoMix 70 FlexPen 100 units/ml suspension for injection in pre-filled pen.

Pharmaceutical Form

Suspension for injection.

The suspension is cloudy, white and aqueous.

Qualitative and quantitative composition

NovoMix 70 Penfill: 1 ml of the suspension contains 100 units soluble insulin aspart*/protamine-crystallised insulin aspart* in the ratio 70/30 (equivalent to 3.5 mg). 1 cartridge contains 3 ml equivalent to 300 units.

NovoMix 70 FlexPen: 1 ml of the suspension contains 100 units soluble insulin aspart*/protamine-crystallised insulin aspart* in the ratio 70/30 (equivalent to 3.5 mg). 1 pre-filled pen contains 3 ml equivalent to 300 units.

* Insulin aspart is produced in Saccharomyces cerevisiae by recombinant DNA technology.

For the full list of excipients, see section 6.1.

Active Ingredient Description
Insulin aspart

The blood glucose lowering effect of insulin aspart is due to the facilitated uptake of glucose following binding of insulin to receptors on muscle and fat cells and to the simultaneous inhibition of glucose output from the liver. Insulin aspart produces a more rapid onset of action compared to soluble human insulin, together with a lower glucose concentration, as assessed within the first four hours after a meal. Insulin aspart has a shorter duration of action compared to soluble human insulin after subcutaneous injection.

List of Excipients

Glycerol
Phenol
Metacresol
Zinc chloride
Disodium phosphate dihydrate
Sodium chloride
Protamine sulfate
Hydrochloric acid (for pH adjustment)
Sodium hydroxide (for pH adjustment)
Water for injections

Pack sizes and marketing

NovoMix 70 Penfill:

3 ml suspension in cartridge (type 1 glass) with a plunger (bromobutyl) and a rubber closure (bromobutyl/polyisoprene). The cartridge contains a glass ball to facilitate resuspension.

Pack sizes of 1, 5 and 10 cartridges. Not all pack sizes may be marketed.

NovoMix 70 FlexPen:

3 ml suspension in cartridge (type 1 glass) with a plunger (bromobutyl) and a rubber closure (bromobutyl/polyisoprene) contained in a pre-filled multidose disposable pen made of polypropylene. The cartridge contains a glass ball to facilitate resuspension.

Pack sizes of 1, 5 and 10 pre-filled pens. Not all pack sizes may be marketed.

Marketing authorization holder

Novo Nordisk A/S, Novo Allé, DK-2880 Bagsværd, Denmark

Marketing authorization dates and numbers

NovoMix 70 Penfill:

EU/1/00/142/017
EU/1/00/142/018
EU/1/00/142/019

NovoMix 70 FlexPen:

EU/1/00/142/020
EU/1/00/142/021
EU/1/00/142/022

Date of first authorisation: 1 August 2000
Date of last renewal: 2 July 2010

Drugs

Drug Countries
NOVOMIX-70 Estonia, Ireland, Israel, Lithuania, Poland, Romania

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.